In addition, in early clinical stages (Table2, T1–2), 92.8% samples of human ACC tissues examined were immunohistochemically stained with antibody against EBP1 with advanced disease (Table2, T3–4), and only 70.8% tissues retained EBP1 staining. This evidence concerns the gene PA2G4 and adrenal cortex carcinoma.